HOPKINTON, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Alseres
Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that Peter Savas,
Chairman and CEO of Alseres Pharmaceuticals, Inc., will present Monday,
November 10th at 2:00pm ET at Rodman & Renshaw Annual Healthcare Conference
at the New York Palace Hotel in New York providing an overview on the
Company and its therapeutic programs.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO )
A live webcast will be available at:
For more information on the conference and speaking companies please go to
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.
Alseres, Cethrin and Altropane are registered trademarks of Alseres
Sharon Correia - 508-497-2360 ext. 224
Alseres Pharmaceuticals, Inc.
Adam Friedman - 212-981-2529 ext. 18
Adam Friedman Associates
|SOURCE Alseres Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved